Study of Deferoxamine Treatment for Adults with Aneurysmal Subarachnoid Hemorrhage up to Age 80

What this Trial Is About

Aneurysmal subarachnoid hemorrhage aSAH is a serious condition with high risk of death and complications shortly after onset. This trial investigates the safety and effectiveness of deferoxamine mesylate DFO, a drug that binds free iron to prevent brain injury caused by iron-related damage. Researchers aim to understand if DFO can improve outcomes for patients admitted with aSAH at the University of Michigan. Participants will be randomly assigned to receive one of two doses of intravenous deferoxamine 32 mgkg or 48 mgkg or a placebo normal saline. The treatment involves three doses administered over three days, each given 24 hours apart at a fixed rate. The trial includes a double-blind design where neither participants nor researchers know the assigned treatment to ensure unbiased results. During the study, patients will be monitored closely with assessments including the Utility-weighted modified Rankin Scale at six months after hospital discharge to measure recovery. Additional evaluations such as cognitive tests, oxygen levels, and brain complication checks will occur during and after treatment. Information will be collected for up to six months post-discharge to understand the long-term effects and safety of the treatments.

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)